U.S. Other Utilities Stock News

NasdaqGS:MMLP
NasdaqGS:MMLPOil and Gas

Martin Midstream Partners (MMLP) Losses Challenge Bullish Valuation Narrative Ahead Of Q1 2026 Earnings

Martin Midstream Partners (MMLP) opened 2026 with Q1 results that keep the focus squarely on profitability, as the latest trailing 12 month figures show total revenue of US$716.1 million and a loss of US$14.4 million, or basic EPS of US$0.37. Over recent quarters, the partnership has seen quarterly revenue range from US$168.7 million to US$192.5 million, while basic EPS has moved between a profit of US$0.09 and losses of up to US$0.21. This sets up an earnings release where investors are...
NasdaqGM:RZLV
NasdaqGM:RZLVSoftware

Rezolve AI (RZLV) Valuation Check After Microsoft Foundry Commerce AI Partnership

Rezolve AI (RZLV) drew fresh attention after announcing its brainpowa commerce-tuned AI model suite is now available within Microsoft Foundry, giving brands access to commerce-focused copilots deployed directly on Microsoft Azure. See our latest analysis for Rezolve AI. Despite the Microsoft Foundry news and a last close of $2.60, Rezolve AI’s recent momentum has been mixed, with a 1-month share price return of 1.17% but a 90-day share price decline of 17.20%, alongside a 1-year total...
NasdaqGS:INBX
NasdaqGS:INBXBiotechs

Why Inhibrx Biosciences (INBX) Is Up 44.3% After Ozekibart Colorectal Cancer Efficacy Update And What's Next

Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI achieved a 20% objective response rate, 87% disease control rate, and manageable safety in heavily pretreated patients with unresectable colorectal cancer, while also advancing a Biologics License Application for ozekibart in conventional chondrosarcoma. These data position ozekibart as a potential first-in-class DR5 agonist with activity across multiple hard-to-treat solid...
NasdaqGS:BPOP
NasdaqGS:BPOPBanks

Popular (BPOP) Net Margin Expansion Reinforces Bullish Efficiency Narrative Ahead Of Q1 2026

Popular (BPOP) has just posted another solid quarter, with Q4 2025 revenue of US$751.8 million and basic EPS of US$3.54, setting the tone as investors look at the new Q1 2026 reporting period. The bank has seen quarterly revenue move from US$689.4 million in Q4 2024 to US$751.8 million in Q4 2025, while basic EPS over that same stretch climbed from US$2.51 to US$3.54, giving you a clear sense of how the income line has scaled alongside the top line. Taken together with an improved net profit...
OTCPK:KTHN
OTCPK:KTHNBanks

Katahdin Bankshares (OTCPK:KTHN) Margin Improvement Challenges Long Term Earnings Slowdown Narrative

Katahdin Bankshares (KTHN) has just put another quarter on the board, with Q4 2025 revenue of US$11.9 million and basic EPS of US$0.99 setting the tone after a year in which trailing net income reached US$10.7 million on revenue of US$44.3 million. Over recent periods the company has seen revenue move from US$9.5 million and EPS of roughly US$0.56 in Q4 2024 to US$11.9 million and US$0.99 respectively in Q4 2025. Trailing basic EPS for the last reported twelve months reached about US$3.37...
OTCPK:ARBV
OTCPK:ARBVBanks

American Riviera Bancorp (OTCPK:ARBV) Net Profit Margin Improvement Challenges Bearish Earnings Narrative

American Riviera Bancorp (ARBV) opened 2026 with Q1 results that build on a solid finish to last year, with Q4 2025 revenue at about US$14.4 million and basic EPS of roughly US$0.80, while trailing twelve month revenue stood at about US$50.4 million and EPS at roughly US$2.18. Over recent quarters, revenue has moved from about US$10.7 million in Q4 2024 to US$14.4 million in Q4 2025, and basic EPS has shifted from roughly US$0.35 to US$0.80. This sets up a story where higher net income and...
NasdaqGS:SGRY
NasdaqGS:SGRYHealthcare

Does Surgery Partners (SGRY) Guidance Cut Reveal a Deeper Shift in Case-Mix Strategy?

Recently, Surgery Partners reduced its earnings guidance after encountering slower surgical case growth, a less favorable payer mix, and reimbursement pressures across its facilities. An important angle is that the company is still prioritizing higher-acuity procedures and robotics investments, suggesting a focus on reshaping its case mix despite these operational challenges. We’ll now explore how this guidance cut, driven by slower case growth and payer mix headwinds, affects Surgery...
NasdaqGS:MEDP
NasdaqGS:MEDPLife Sciences

Medpace (MEDP) Margin Slippage Challenges Bullish Narratives Despite Solid Q4 EPS

Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$2.5 billion and EPS of US$15.64. Over recent quarters the company has seen revenue move from US$533.3 million in Q3 2024 to US$708.5 million in Q4 2025, while quarterly basic EPS has ranged from US$3.11 to US$4.78 across the same stretch. With trailing net profit margins at 17.8% versus 19.2% the...
NYSE:MSB
NYSE:MSBMetals and Mining

Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives

Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...
NasdaqCM:FMAO
NasdaqCM:FMAOBanks

Farmers & Merchants Bancorp (FMAO) Net Interest Margin Improvement Tests Bullish Community Narratives

Farmers & Merchants Bancorp (FMAO) has put fresh numbers on the board, with Q4 2025 revenue of about US$31.9 million and basic EPS of US$0.70, supported by net income of US$9.7 million as the latest marker ahead of its Q1 2026 reporting period. The business has seen revenue move from US$26.6 million and EPS of US$0.59 in Q4 2024 to US$31.9 million and EPS of US$0.70 in Q4 2025. Trailing 12 month earnings growth of 29.4% and a 27.6% net margin frame a profitability profile that many investors...
NasdaqGM:SMBC
NasdaqGM:SMBCBanks

Southern Missouri Bancorp (SMBC) Net Interest Margin Holds At 3.57% Reinforcing Growth Narrative

Southern Missouri Bancorp (SMBC) opened Q3 2026 with Q2 results that put revenue and earnings in clear focus, reporting total revenue of US$48.0 million and basic EPS of US$1.62 on net income of US$18.1 million. The company has seen revenue move from US$41.7 million with EPS of US$1.10 in Q1 2025 to US$45.1 million and EPS of US$1.40 in Q4 2025, then to US$48.0 million and EPS of US$1.62 in Q2 2026. This latest report can be viewed as part of a steady earnings story that investors can now...
NYSE:OGS
NYSE:OGSGas Utilities

A Look At ONE Gas (OGS) Valuation As Recent Momentum Meets Tight Undervaluation Estimates

ONE Gas (OGS) has drawn fresh attention after its recent trading session, with the stock closing at $88.76. For investors, the move brings added focus to how the regulated utility’s fundamentals line up. See our latest analysis for ONE Gas. The latest move to $88.76 comes after a 14.93% 90 day share price return and a 16.97% total shareholder return over the past year, hinting that momentum has been building rather than fading. If this kind of steady utility performance has you thinking about...
NYSE:TMO
NYSE:TMOLife Sciences

Thermo Fisher Scientific (TMO) Margin Hold At 15% Tests Long Term Earnings Concerns

Thermo Fisher Scientific (TMO) has just put fresh numbers on the table, with Q4 2025 revenue of US$12.2b and basic EPS of US$5.22 setting the tone against a trailing twelve month EPS of US$17.78 on revenue of US$44.6b, alongside net income of US$6.7b. The company has seen quarterly revenue move from US$10.6b in Q3 2024 to US$12.2b in Q4 2025, while basic EPS over the same period went from US$4.27 to US$5.22. This gives investors a clear read on top line scale and earnings power as they assess...
NasdaqGS:KRNY
NasdaqGS:KRNYBanks

Kearny Financial (KRNY) Net Interest Margin Near 2.1% Challenges Bearish Narratives

Kearny Financial (KRNY) has just reported Q3 2026 results with quarterly revenue in the low US$40 million range and basic EPS of about US$0.15, set against a trailing twelve month EPS of US$0.52 that reflects the shift back into profitability. Over recent periods, revenue has moved from US$36.96 million in Q1 2025 to US$42.97 million in Q2 2026, while quarterly EPS has stepped from roughly US$0.10 to just over US$0.15. This gives investors a clearer read on how earnings now sit relative to...
NasdaqGS:FBNC
NasdaqGS:FBNCBanks

First Bancorp (FBNC) Q1 Net Income Rebound Tests Bearish Regional Bank Narratives

First Bancorp (FBNC) opened 2026 with Q1 results that put the focus squarely on the income statement, reporting total revenue of US$119.2 million and basic EPS of US$1.13, backed by trailing twelve month revenue of US$393.3 million and EPS of US$2.93. Over recent periods the company has seen quarterly revenue move from US$65.2 million in Q4 2024 to US$104.7 million in Q1 2025, US$108.8 million in Q2, US$86.2 million in Q3 and US$79.2 million in Q4, while EPS shifted from US$0.09 to US$0.88,...
NasdaqCM:BLTE
NasdaqCM:BLTEPharmaceuticals

Is Tinlarebant’s Rolling NDA for Stargardt Disease Altering The Investment Case For Belite Bio (BLTE)?

Belite Bio recently initiated a rolling New Drug Application submission to the U.S. FDA for tinlarebant, an investigational oral therapy for Stargardt disease type 1, following completion of a Phase 3 trial and multiple regulatory designations including Breakthrough Therapy and Orphan Drug status. This step positions tinlarebant as a potential first approved treatment for Stargardt disease and highlights Belite Bio’s advancing regulatory and commercialization plans in rare retinal...
NYSE:V
NYSE:VDiversified Financial

Visa (V) Valuation Check After Recent Share Price Weakness

Visa Stock Snapshot After Recent Price Moves Visa (V) has seen mixed share performance recently, with a 1 day return of about a 1% decline, a 2% decline over the past week, and a small positive move over the past month. Over the past 3 months, the stock shows roughly a 5% decline and the year to date return is about an 11% decline, while the 1 year total return is about a 7% decline for investors holding through this period. See our latest analysis for Visa. Visa’s recent share price...
NYSE:TDC
NYSE:TDCSoftware

What Teradata (TDC)'s Transparent AI Analyst Agent Launch on Microsoft Marketplace Means For Shareholders

In April 2026, Teradata Corporation announced that its enterprise-grade Analyst Agent became available on Microsoft Marketplace, giving Azure customers a no-code, conversational analytics tool that orchestrates complex SQL queries and visualizations within their existing Teradata and Azure environments. A distinctive feature of this launch is Teradata’s Agent Telemetry, which makes the AI agent’s reasoning observable and auditable, allowing enterprises to configure custom quality signals and...
NasdaqGS:ROKU
NasdaqGS:ROKUEntertainment

Roku (ROKU) Valuation Check As Solid Results And Ad Platform Momentum Draw Fresh Investor Focus

Roku (ROKU) is back in focus after a strong six month run, outpacing the S&P 500. The stock has drawn renewed attention alongside solid quarterly results, higher streaming hours, improving free cash flow margin, and growing interest ahead of upcoming earnings. See our latest analysis for Roku. The recent 30 day share price return of 20.26% and a 1 year total shareholder return of 77.82% suggest momentum has been building, although the 5 year total shareholder return of a 67.77% loss shows...
NYSE:DOV
NYSE:DOVMachinery

Dover (DOV) Margin Reset To 13.6% Tests Quality Growth Narrative Heading Into Q1 2026

Dover (DOV) kicked off Q1 2026 against a backdrop of recent quarterly revenue between US$1.87 billion and US$2.10 billion and basic EPS ranging from US$1.74 to US$2.21 through 2025, with trailing 12 month revenue at about US$8.09 billion and EPS at US$8.01. Over that same trailing period, revenue has stayed in a tight band around US$7.72 billion to US$8.09 billion, while EPS moved between US$7.55 and US$8.01. This provides a clear sense of how top line and per share earnings have been...
NYSE:TRGP
NYSE:TRGPOil and Gas

How Investors May Respond To Targa Resources (TRGP) 25% Dividend Hike Signaling Management Confidence

Targa Resources Corp. recently approved a 25% increase in its quarterly cash dividend to US$1.25 per share, or US$5.00 annually, for the first quarter of 2026, payable on May 15 to shareholders of record as of April 30. This step, consistent with earlier guidance, highlights how management is using higher cash returns to signal confidence in the business ahead of its upcoming earnings release. Next, we’ll examine how this 25% dividend increase interacts with Targa’s growth investments and...
NYSE:AMTM
NYSE:AMTMProfessional Services

How Investors Are Reacting To Amentum Holdings (AMTM) Naming New IR Chief Amid Artemis II Role

Earlier this month, Amentum Holdings appointed Joseph (Joe) DeNardi as Senior Vice President and Head of Investor Relations, while also highlighting its role in providing critical ground systems operations and recovery support for NASA’s crewed Artemis II mission. The combination of a new investor relations leader with deep sector expertise and Amentum’s hands-on contribution to Artemis II underscores the company’s focus on both capital markets engagement and complex, mission-critical space...
NYSE:ESE
NYSE:ESEMachinery

Is It Too Late To Consider ESCO Technologies (ESE) After A 102% One Year Rally?

Wondering whether ESCO Technologies at around US$318.83 still offers value, or if most of the opportunity is already reflected in the price. The stock has posted returns of 6.3% over the last week, 15.2% over the past month, 61.3% year to date and 102.2% over the past year, with a 3 year return of 242.0% and 5 year return of 190.3%. Recent coverage has focused on ESCO Technologies as a capital goods player whose share price performance has drawn fresh attention from investors seeking quality...
NasdaqGS:CSX
NasdaqGS:CSXTransportation

CSX (CSX) Margin Compression Challenges Bullish Narratives Heading Into Q1 2026 Earnings

CSX (CSX) has just opened its 2026 reporting year with investors still focused on the recent Q4 2025 numbers, where revenue came in at US$3.5b and basic EPS was US$0.39, setting the reference point for how Q1 performance will be judged. Over the past few quarters, revenue has held in a tight band around US$3.4b to US$3.6b, while basic EPS moved between US$0.34 and US$0.44, giving a clear read on how small shifts in volumes and pricing flow through to earnings. With trailing net margins at...